Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China

Diabetic Medicine

Volumn 34, Issue 4, 2017, Pages 505-513

  Yi, M ^a   Chen, R P ^a   Yang, R ^a   Chen, H ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL RADIOGRAPHY; ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOCHEMISTRY; BODY MASS; CHINA; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; RISK FACTOR; ABDOMINAL OBESITY; AGE; CROSS-SECTIONAL STUDY; DIABETIC NEUROPATHY; DIAGNOSTIC IMAGING; HYPERURICEMIA; LIVER CIRRHOSIS; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; SEX FACTOR; STATISTICAL MODEL;

ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; CHINA; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERURICEMIA; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OBESITY, ABDOMINAL; OVERWEIGHT; PREVALENCE; SEX FACTORS; TRIGLYCERIDES;

EID: 84987896423     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13174     Document Type: Article

References (36)

1. Boyraz M, Hatipoglu N, Sari E, Akcay A, Taskin N, Ulucan K et al. Non-alcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria. Obes Res Clin Pract 2014; 8: e356–363.
2. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388–1393.
3. Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A et al. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol 2007; 22: 794–800.
4. Puig J, Blasco G, Daunis IEJ, Loshuertos E, Codina J, Cuba V et al. Nonalcoholic fatty liver disease and age are strong indicators for atherosclerosis in morbid obesity. Clin Endocrinol 2015; 83: 180–6.
5. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112–117.
6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592–1609.
7. Imhof A, Kratzer W, Boehm B, Meitinger K, Trischler G, Steinbach G et al. Prevalence of non-alcoholic fatty liver and characteristics in overweight adolescents in the general population. Eur J Epidemiol 2007; 22: 889–897.
8. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539–553.
9. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: J Dig Dis 2011; 12:38–44. [published in Chinese in Chinese J Hepatol 2010; 18:163–166.]
10. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441–1447.
11. Society. CD. China Guideline for type 2 diabetes. Peking: Peking University Medical Press, 2013.
12. Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg 2006; 108: 477–481.
13. Kdoqi. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49(Suppl. 2): S12–154.
14. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2937–2944.
15. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124–131.
16. Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007; 47: 239–244.
17. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013; 178: 38-45.
18. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17–26.
19. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132–138.
20. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005; 129: 375–378.
21. Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61: 409–415.
22. Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 2016; 65: 1359–1368.
23. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009; 13: 9–19.
24. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44–52.
25. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722–728.
26. Bedogni G, Gastaldelli A, Manco M, De Col A, Agosti F, Tiribelli C et al. Relationship between fatty liver and glucose metabolism: a cross-sectional study in 571 obese children. Nutr Metab Cardiovasc Dis 2012; 22: 120–126.
27. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22–29.
28. Meyer C, Woerle HJ, Dostou JM, Welle SL, Gerich JE. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab 2004; 287: E1049–1056.
29. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003; 163: 1306–1316.
30. Firneisz G, Somogyi A. Serum level of soluble CD26/dieptidyl peptidase-4 (DPP-4) activity correlates with other liver disease biomarkers both in Asian and European patients. Transl Res 2012; 160: 95–96.
31. Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L, Steinert RE, Heim MH et al. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PloS One 2014; 9: e87488.
32. Fiatarone JR, Coverdale SA, Batey RG, Farrell GC. Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis. J Gastroenterol Hepatol 1991; 6: 585–590.
33. Sanches PL, de Piano A, Campos RM, Carnier J, de Mello MT, Elias N et al. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy. J Clin Lipidol 2014; 8: 265–272.
34. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araujo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arg Gastroenterol 2012; 49:89–96.
35. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986; 292: 13–15.
36. Morling JR, Fallowfield JA, Guha IN, Nee LD, Glancy S, Williamson RM et al. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. J Hepatol 2014; 60: 384–391.